When was Epignostix founded?

Epignostix was founded in 2022 and raised its 1st funding round 2 years after it was founded.

Where is Epignostix located?

Epignostix is headquartered in Heidelberg, Germany.

How many employees does Epignostix have?

As of Jun 30, 2026, the latest employee count at Epignostix is 16.

Is Epignostix a funded company?

Epignostix is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on Jul 02, 2024.

When was the latest funding round of Epignostix?

Epignostix's latest funding was a $***** Seed round on Jul 02, 2024, with participation from 8 investors.

Where does Epignostix rank among its competitors?

Epignostix ranks 1547th amongst 3250 active competitors, of which 1119 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Epignostix?

Epignostix's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Epignostix - 2026 Company Profile, Team, Funding & Competitors

Epignostix is a seed company based in Heidelberg (Germany), founded in 2022 by Martin Sill and Daniel Schrimpf. It operates as a Developer of DNA methylation-based therapeutics for tumor classification. Epignostix has raised $4.62M in funding. The company has 3250 active competitors, including 1119 funded and 771 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Developer of DNA methylation-based therapeutics for tumor classification. It revolutionize tumor classification by harnessing the power of methylation-based models to improve diagnosis, prognosis, and treatment decisions.

Key Metrics

Founded Year

2022

Location

Heidelberg, Germany

Stage

Seed

Total Funding

$4.62M in 1 round

Latest Funding Round

Seed, Jul 02, 2024, $*****

Investors

HTGF & 8 more

Ranked

1547^th among 3250 active competitors

Employee Count

16 as on Jun 30, 2026

Similar Companies

Jazz Pharmaceuticals & 2973 more

View Epignostix's full profile

Epignostix has raised a total funding of $4.62M over 1 round. Its latest funding round was a Seed round on Jul 02, 2024 for $*****. 8 investors participated in its latest round. Epignostix has 9 institutional investors.

Here is the list of recent funding rounds of Epignostix:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 02, 2024	9331240	Seed	3214387	5118852	2850192	4836464

Access funding benchmarks and valuations. Sign up today!

View details of Epignostix's funding rounds and investors

The founders of Epignostix are Martin Sill and Daniel Schrimpf. Helge Lubenow is the CEO of Epignostix.

Here are the details of Epignostix's key team members:

Martin Sill: Co-Founder and Head of Data Science of Epignostix.
Daniel Schrimpf: Co-Founder of Epignostix.
Helge Lubenow: CEO of Epignostix.

View details of Epignostix's Founder profiles and Board Members

Epignostix's employee count trend

Epignostix has 16 employees as of Jun 26. Here is Epignostix's employee count trend over the years:

Uncover Epignostix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Epignostix include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Epignostix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	80/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	Khosla Ventures, True North & 23 others	71/100
1547th	Epignostix 2022, Heidelberg (Germany), Seed	Developer of DNA methylation-based therapeutics for tumor classification	$4.62M	HTGF, CARMA FUND & 7 others	33/100